Ovid Therapeutics (OVID) Stock Analysis & AI Equity Report
Ovid Therapeutics (OVID) overview
Ovid Therapeutics (OVID) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 7.3m and operating profit of USD -42.4m; the year-end share price was 1.63 USD and market capitalisation was USD 212m. Ovid Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ovid Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Ovid Therapeutics
Ovid Therapeutics develops small molecule medicines for brain disorders. Its potential central nervous system therapies target biological mechanisms associated with neuronal hyperexcitability, including neurotransmitters and ion channels. Clinical programs address drug-resistant focal onset seizures, developmental and epileptic encephalopathies, psychosis associated with Parkinson’s disease and Lewy body dementia, and schizophrenia. Preclinical programs address other psychosis and mood disorders.
Generate the Ovid Therapeutics report
Ovid Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ovid Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Ovid Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.